Inactivated Covid-19 vaccine of Valneva is expected for 2nd Q 2022

Friday, 26 November 2021 00:09

life-science Karriere Services, Foto: © Gustavo Fring_pexelsValneva SE has signed an Advance Purchase Agreement (APA) with the European Commission (EC) to supply up to 60 million doses of its inactivated COVID-19 vaccine candidate, VLA2001, over two years. Valneva expects to deliver 24.3 million doses during the second and third quarters of 2022, subject to approval of VLA2001 by the European Medicines Agency.

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), is a specialty vaccine company. Under the terms of the agreement following final review of the volumes by each of the European Union (EU) Member States, Valneva expects to deliver 24.3 million doses during the second and third quarters of 2022, subject to approval of VLA2001 by the European Medicines Agency (EMA). The EC has the option to increase this initial firm purchase order up to a total of 60 million doses, the remainder of which would be delivered in 2023.

The advantages of inactivated vaccines confirmed

Thomas Lingelbach, Chief Executive Officer of Valneva, said, “We are extremely pleased that the European Commission and the Member States have completed this purchase agreement and are eager to help address the ongoing pandemic. We continue to receive messages from people across the world requesting access to an inactivated vaccine. Our Phase 3 results confirmed the advantages often associated with inactivated vaccines and we continue to believe that our differentiated vaccine candidate can make an important contribution to the global fight against the COVID-19 pandemic.”

Rolling review with EMA

Franck Grimaud, Chief Business Officer of Valneva, commented, “We are looking forward to getting the rolling review with EMA underway now that the rapporteurs have been appointed. The latest COVID-19 wave in Europe underlines the need for an alternative vaccine and we have some vaccine inventory ready to be used as soon as we receive EMA approval. Confirmation of the EC agreement will also allow us to optimize our manufacturing strategy for VLA2001.”

Valneva reported positive Phase 3 results for VLA2001 in October 2021[2]. VLA2001 demonstrated superiority in terms of neutralizing antibody titer levels against the active comparator vaccine, AstraZeneca’s AZD1222, as well as non-inferiority in terms of seroconversion rates and a significantly better tolerability profile.

About VLA2001

VLA2001 is currently the only whole virus, inactivated, adjuvanted vaccine candidate against COVID-19 in clinical trials in Europe. It is intended for active immunization of at-risk populations to prevent carriage and symptomatic infection with COVID-19 during the ongoing pandemic and potentially later for routine vaccination including addressing new variants. VLA2001 may also be suited for boosting, as repeat booster vaccinations have been shown to work well with whole virus inactivated vaccines. VLA2001 is produced on Valneva’s established Vero-cell platform, leveraging the manufacturing technology for Valneva’s licensed Japanese encephalitis vaccine, IXIARO®. VLA2001 consists of inactivated whole virus particles of SARS-CoV-2 with high S-protein density, in combination with two adjuvants, alum and CpG 1018. This adjuvant combination has consistently induced higher antibody levels in preclinical experiments than alum-only formulations and shown a shift of the immune response towards Th1. CpG 1018 adjuvant, supplied by Dynavax Technologies Corporation (Nasdaq: DVAX), is a component of the US FDA- and EMA-approved HEPLISAV-B® vaccine. The manufacturing process for VLA2001, which has already been upscaled to final industrial scale, includes chemical inactivation to preserve the native structure of the S-protein. VLA2001 is expected to conform with standard cold chain requirements (2 degrees to 8 degrees Celsius).

Forward-Looking Statements

This press release contains certain forward-looking statements relating to the business of Valneva, including with respect to the progress, timing, design, data read-outs, anticipated results and completion of clinical trials and regulatory review processes for VLA2001. In addition, even if the actual results or development of Valneva are consistent with the forward-looking statements contained in this press release, those results or developments of Valneva may not be indicative of future results. In some cases, you can identify forward-looking statements by words such as “could,” “should,” “may,” “expects,” “anticipates,” “believes,” “intends,” “estimates,” “aims,” “targets,” or similar words. These forward-looking statements are based on the current expectations of Valneva as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of Valneva could be affected by, among other things, uncertainties involved in the development and manufacture of vaccines, unexpected clinical trial results, unexpected regulatory actions or delays, competition in general, currency fluctuations, the impact of the global and European credit crisis, the ability to obtain or maintain patent or other proprietary intellectual property protection, the cancellation of existing contracts, including but not limited to the HMG Supply Agreement, and the impact of the COVID-19 pandemic, the occurrence of any of which could substantially harm Valneva’s business, financial condition, prospects and results of operations. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made during this presentation will in fact be realized. Valneva is providing the information in this press release as of the date hereof and disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwi

 

(GZ)
Quelle:Valneva
Foto:

Bei Rückfragen zum Artikel wenden Sie sich
bitte direkt an die im Artikel angegebene Kontaktadresse.

.fusion-widget-area-1 {padding:0px 0px 0px 0px;}.fusion-widget-area-1 .widget h4 {color:#4c5166;}.fusion-widget-area-1 .widget .heading h4 {color:#4c5166;}.fusion-widget-area-1 .widget h4 {font-size:24px;}.fusion-widget-area-1 .widget .heading h4 {font-size:24px;}
jobbörse für Naturwissenschaftler

Der Beitrag Inactivated Covid-19 vaccine of Valneva is expected for 2nd Q 2022 erschien zuerst auf Jobbörse und Netzwerk für Naturwissenschaftler /-innen.

Read more https://life-science.eu/inactivated-covid-19-vaccine-of-valneva-is-expected-for-2nd-q-2022/

Published in life-science
  • FEMS Affiliates Letter - July 2022
    As member of the ÖGMBT you are automatically also member of the Federation of European Microbiology Societies (FEMS). The FEMS Affiliates Letter of July 2022 has the following content:   1. Microbiology News and Events 2. The FEMS Journals 3. Policy Corner 4. Grants Corner 5. Opportunities 6. Extras  
    08.08.2022,
  • European Researchers Night „Life is Science in a Digital World – LiS-Dig”
    Am 30. September 2022 heißt es wieder „Life is Science“! Das Mitmachevent für Groß und Klein wird heuer von der FH St. Pölten und der acib GmbH gemeinsam ausgerichtet und neben einem tollen Ausstellerbereich in Niederösterreich (St. Pölten) mit vielen spannenden Mitmachstationen wird es auch einige Experimentier-Workshops in Graz geben. Sie möchten in diesem Rahmen Ihre Forschung nicht nur präsentieren sondern erlebbar machen? Melden Sie Ihren Beitrag bis 31. Juli…
    05.07.2022,
  • FEMS Affiliates Letter - June 2022
    As member of the ÖGMBT you are automatically also member of the Federation of European Microbiology Societies (FEMS). The FEMS Affiliates Letter of June 2022 has the following content:   1. Microbiology News and Events 2. The FEMS Journals 3. Policy Corner 4. Grants Corner 5. Opportunities 6. Extras  
    29.06.2022,
  • The Peter and Traudl Engelhorn Foundation announces the call for the research award 2023
    Peter und Traudl Engelhorn-Stiftung/Foundation Supporting Life Sciences Call for Proposals Research Prize 2023   Topic "Chain Folding, Macromolecular Aggregation and Controlled Hydrolysis of Proteins and/or DNA/RNA – Fundamentals and Perspectives for Medical Therapies” Eligibility Requirements: The Peter and Traudl Engelhorn Foundation for the advancement of Life Sciences invites high potential young scientists to apply for the Research Prize 2023. Applicants not older than 35 years, living/working in Austria, Germany or…
    27.06.2022,
  • FEMS - Get Involved bulletin – June 2022
    The FEMS Get involved bulletin is out! Read the June issue with microbiology research, events and calls. In this bulletin:l FEMS Conference #FEMSmicroBlog Opportunities Board FEMS Journal News   Deadlines: Research and Training Grants: 1 July 2022 Industry Placement Grants: 1 August 2022 Meeting Attendance Grants: 1 September 2022   The ÖGMBT has a very wide international network and is a member of several relevant scientific societies like FEMS. ÖGMBT…
    24.06.2022,
  • Submission deadline for the Life Science Austria Awards extended until June 15, 2022
    The submission deadline for the "Life Science Awards Austria 22" has been extended until June 15, 2022.
    31.05.2022,
  • FEMS - Get Involved bulletin – May 2022
    The FEMS Get involved bulletin is out! Read the May issue with microbiology research, events and calls. In this bulletin: FEMS Summer School FEMS Conference Story writing competition #FEMSmicroBlog FEMS Journal News   Deadlines: FEMS Summer School: 1 June 2022 Meeting Organizer Grants: 1 June 2022 Research and Training Grants: 1 July 2022 Industry Placement Grants: 1 August 2022 Meeting Attendance Grants: 1 September 2022   The ÖGMBT has a…
    31.05.2022,
  • Short Story Writing Competition – How Will Microbiology Change Our Future?
    Do you have ideas for crazy stories about how microbiology could change our future? Then join the competition. The #FEMSmicroBlog is opening a short story writing competition to showcase how microbiology touches our lives. Deadline for submission is 30 June 2022 For more information please look here:   https://fems-microbiology.org/short-story-writing-competition-how-will-microbiology-change-our-future/    
    30.05.2022,
  • FEMS Affiliates Letter - April 2022
    As member of the ÖGMBT you are automatically also member of the Federation of European Microbiology Societies (FEMS). The FEMS Affiliates Letter of April 2022 has the following content:   1. Microbiology News and Events 2. The FEMS Journals 3. Policy Corner 4. Grants Corner 5. Opportunities 6. Extras  
    06.05.2022,
  • FEMS - Get Involved bulletin – April 2022
    The FEMS Get involved bulletin is out! Read the April issue with microbiology research, events and calls. In this bulletin: #FEMSmicroBlog, Podcast & Opportunities Board FEMS Journal News   Deadlines: Meeting Organizer Grants: 1 June 2022 Research and Training Grants: 1 July 2022 Industry Placement Grants: 1 August 2022 Meeting Attendance Grants: 1 September 2022   The ÖGMBT has a very wide international network and is a member of several…
    29.04.2022,
  • Erklärvideo zu Totimpfstoffen gegen COVID-19
    Das neue Erklärvideo von Open Science "SARS-CoV-2: Totimpfstoffe" ist fertig - rechtzeitig zum Start der Impfung mit dem Proteinimpfstoff von Novavax! Das Video, das in Kooperation mit dem Doktoratskolleg RNA-Biologie und der FH Campus Wien entstanden ist, erklärt, wie inaktivierte Ganzvirus- und Proteinimpfstoffe gegen COVID-19 hergestellt werden, was sie beinhalten und wie sie wirken.    
    02.03.2022,
  • Labbuddy - Training lab teaching
    We developed a training on teaching in the lab, in which we will provide teachers with tips and tricks that will help them inspire student learning in the lab. Laboratory course teaching fundamentals Teaching seems easy…….. ………until the moment you need to teach! Teaching is a true profession, but everyone can learn how to teach. Do you need to teach because of your Ph.D. study, or are you a teacher…
    27.01.2022,
    by
  • Open Call for Applications: 4 Fellowships 4 Entrepreneurs 2022
    Do you have an entrepreneurial idea that you want to develop under the guidance of experts? Are you ready to sound out your entrepreneurial spirit? Then the LBG Career Center might have the right program for you! Within the 4 Fellowships 4 Entrepreneurs program, you will build foundational knowledge about entrepreneurship, receive support on your journey to launching your ideas, and start on the path to becoming an entrepreneur.Throughout 9 months,…
    18.01.2022,
    by
  • FEBS Junior Sections Talk Series 2022
    FEBS Junior Sections Talk Series 2022 We have planned a series of monthly talks for 2022, alternating academic and career topics, each organized by a Junior Section from a different country. 13th January. Academic. Organized by Junior-GBM (the Junior Section of the German Society, GBM). A talk by Dr Andreas Schlundt, from Goethe University Frankfurt, on “The roles of sequence, structure and dynamics for specific RNA-recognition by proteins". Watch the recorded…
    18.01.2022,
    by
  • BCF Career events
    Activate your career dreams in Life Sciences with BCF Career Are you a newly graduate looking for your first job, a (young) professional looking for the next step in your career or simply interested in enhancing your career? Join our (online) BCF Career Events:   17 February 2022 - BCF Career Event Benelux - Online edition 19 May 2022 - BCF Career Event Netherlands - Jaarbeurs Utrecht 16 November 2022…
    29.12.2021,
    by
  • Chemiereport 8/21
    Chemiereport 8/12- the 8th edition of Chemiereport is out featuring news from life science world in Austria and most importantly covering article under the title  ”ÖGMBT presents career opportunities in the Life Sciences”.  In the article ÖGMBT interim manager Andrea Bauer speaks on all the ways ÖGMBT and ÖGMBT-YLSA explore possibilities for young life scientists in the field. More so by organizing variety of career events, presenting job profiles on…
    29.12.2021,
    by
  • IUBMB grants
    IUBMB grants- There is variety of travel and fellowship grants for young researchers from International Union of Biochemistry and Molecular Biology with upcoming deadlines.  Check it out here.
    04.11.2021,
    by
  • FEBS-IUBMB-ENABLE 2022 Symposium – a PhD and Postdoc meeting
    FEBS-IUBMB-ENABLE are now looking for an academic institution (either a university or a research institution) in Europe with a strong research background in molecular life sciences and an active PhD community to host the November 2022 conference. This event will be organized by a committee of young researchers belonging to the four ENABLE institutions (core institutions, as listed above) plus the selected host institution (associated institution). It will be organized…
    25.08.2021,
    by
  • FEBS junior initiative
    To bring together young scientists from all over Europe, the junior sections of the ÖGMBT (Austria), SIB (Italy), SEBBM (Spain) and GBM (Germany) have collaborated with FEBS to establish a platform for exchange within the FEBS Network. For this, FEBS has created an open Room for the Junior Sections of FEBS Constituent Societies. All young members from the FEBS societies are welcome to sign up to the FEBS Network and become a member of the room using the following…
    25.08.2021,
    by
  • Explaining THT Biomaterials in 3 Minutes to Scientists
    This is our supplemental 3 minute video for the 11th World Congress on Alternatives and Animal Use in the Life Sciences (WC11) from 23 August - 2 September 2021, our abstract ID=625: https://www.youtube.com/watch?v=cEArIBSnKsc&feature=youtu.be Enjoy watching (and sorry for the poor sound - we will improve)!
    16.07.2021,
  • Global Manager Quality Control – Animal Nutrition Health – m/f/d
    Global Manager Quality Control – Animal Nutrition & Health – m/f/d ERBER GroupDer Beitrag Global Manager Quality Control – Animal Nutrition & Health – m/f/d erschien zuerst auf Jobbörse und Netzwerk für Naturwissenschaftler /-innen....
    17.08.2022,
  • Technik Experte für unsere biopharmazeutische Zellkulturanlage im Upstream (w/m/d)
    Technik Experte für unsere biopharmazeutische Zellkulturanlage im Upstream (w/m/d) Boehringer Ingelheim RCVDer Beitrag Technik Experte für unsere biopharmazeutische Zellkulturanlage im Upstream (w/m/d) erschien zuerst auf Jobbörse und Netzwerk für Naturwissenschaftler /-innen....
    13.08.2022,
  • Analytical Specialist – Corporate QC Method Validation (m/f/d)
    Analytical Specialist – Corporate QC Method Validation (m/f/d) Octapharma Pharmazeutika Produktionsges.m.b.H.Der Beitrag Analytical Specialist – Corporate QC Method Validation (m/f/d) erschien zuerst auf Jobbörse und Netzwerk für Naturwissenschaftler /-innen....
    10.08.2022,
  • “Strom statt Pillen”
    v. l: Eugenijus Kaniusas, Babak Dabiri und Andreas Dickinger2020 wurde es vorausgesagt und 2022 in der Klinik bestätigt: Eugenijus Kaniusas und seine Partner konnten zeigen, dass die Stimulation des aurikulären Vagusnervs eine entzündungshemmende Wirkung bei schweren Covid-19-Verläufen hat.Elektrischer EntzündungshemmerDie Vagusnerv-Stimulation...
    03.08.2022,
  • Teamlead Analytic Laboratory – m/f/d
    Teamlead Analytic Laboratory – m/f/d ERBER GroupDer Beitrag Teamlead Analytic Laboratory – m/f/d erschien zuerst auf Jobbörse und Netzwerk für Naturwissenschaftler /-innen....
    03.08.2022,
  • Corporate Strategic Purchaser – Medical Devices (m/f/d)
    Corporate Strategic Purchaser – Medical Devices (m/f/d) Octapharma Pharmazeutika Produktionsges.m.b.H.Der Beitrag Corporate Strategic Purchaser – Medical Devices (m/f/d) erschien zuerst auf Jobbörse und Netzwerk für Naturwissenschaftler /-innen....
    03.08.2022,
  • Inaktivierter Covid-19 Impfstoff von Valneva kann ausgeliefert werden
    Auch wenn Corona nicht mehr das beherrschende Thema in den Medien ist, so steht die Impfung nach wie vor im Raum. Valneva SE bestätigt nun , dass in den kommenden Wochen 1,25 Millionen Dosen des inaktivierten COVID-19-Ganzvirusimpfstoff VLA2001 an die Mitgliedsstaaten der EU geliefert werden können. Dieser Impfstoff ist der erste regulär z...
    02.08.2022,
  • Daten für das Pflegeheim
    Damit Daten dort hin kommen, wo sie einen Nutzen bringen, hat die MedUni Graz gemeinsam mit anderen Universitäten das OPINION Lab ins Leben gerufen, damit neueste Forschungserkenntnisse in den Alltag der Pflegepraxis einfließen können.Projekt OPINION Lab für einen besseren Datenzugang für die PflegeWie in der Medizintechnik oder der Pharmazie gilt...
    31.07.2022,
  • Vernetzung – Erfahrungsaustausch – gemeinsame Programme…
    … sind die Ziele von Arqus, der Hochschul-Allianz von 9 europäischen Universitäten. Die Uni Graz geht nun mit Arqus und einer 14,4 Millionen-Förderung der EU in die nächsten vier Jahre und damit in die zweite Periode.Zusammenschluss über den Kontinent verteiltMit einem Rekordbudget von 272 Millionen Euro fördert die Europäische Kommission 16...
    29.07.2022,
  • Early Pipeline Regional Medical Affairs Manager (f/m/d)
    Early Pipeline Regional Medical Affairs Manager (f/m/d) Boehringer Ingelheim RCVDer Beitrag Early Pipeline Regional Medical Affairs Manager (f/m/d) erschien zuerst auf Jobbörse und Netzwerk für Naturwissenschaftler /-innen....
    27.07.2022,